Manjari Pandey
Overview
Explore the profile of Manjari Pandey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma M, Pandey M, Singh U, Sachan R, Sankhwar P
J Family Med Prim Care
. 2024 Mar;
13(1):265-270.
PMID: 38482325
Objective: Vaginal pH has been suggested to be one of the causative factors, responsible for variation in prostaglandin efficacy for induction of labour. The purpose of this study was to...
2.
Ballo M, Qualls K, Michael L, Sorenson J, Baughman B, Karri-Wellikoff S, et al.
Neurooncol Adv
. 2022 Oct;
4(1):vdac150.
PMID: 36249289
Background: Determinates of tumor treating fields (TTFields) usage in patients receiving combined modality therapy for primary IDH wild-type glioblastoma are currently unknown. Methods: Ninety-one patients underwent maximal debulking surgical resection,...
3.
Pandey M, Xiu J, Mittal S, Zeng J, Saul M, Kesari S, et al.
Neurooncol Adv
. 2022 Jul;
4(1):vdac096.
PMID: 35821680
Background: The genomic and overall biologic landscape of glioblastoma (GB) has become clearer over the past 2 decades, as predictive and prognostic biomarkers of both de novo and transformed forms...
4.
Stein M, Pandey M, Xiu J, Tae H, Swensen J, Mittal S, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100709
Purpose: Tumor mutational burden (TMB) is a developing biomarker in non-small-cell lung cancer (NSCLC). Little is known regarding differences between TMB and sample location, histology, or other biomarkers. Methods: A...
5.
Nguyen N, Redfield J, Ballo M, Michael M, Sorenson J, Dibaba D, et al.
CNS Oncol
. 2021 Sep;
10(3):CNS74.
PMID: 34486380
To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. A retrospective study of 109 glioblastoma patients was performed to determine the...
6.
Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh S, et al.
BMC Neurol
. 2021 Aug;
21(1):316.
PMID: 34391386
No abstract available.
7.
Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh S, et al.
BMC Neurol
. 2021 Jun;
21(1):231.
PMID: 34162346
Background: Gliosarcoma (GS) refers to the presence of mesenchymal differentiation (as seen using light microscopy) in the setting of glioblastoma (GB, an astrocytoma, WHO Grade 4). Although the same approach...
8.
Pandey R, Johnson N, Cooke L, Johnson B, Chen Y, Pandey M, et al.
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33546249
Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene sequences, copy number alterations, gene-fusions, and with immunohistochemistry (IHC), is a valuable tool in clinical decision making...
9.
Nabors L, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al.
J Natl Compr Canc Netw
. 2020 Nov;
18(11):1537-1570.
PMID: 33152694
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement...
10.
Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, et al.
Neurooncol Adv
. 2020 Mar;
2(1):vdaa018.
PMID: 32201861
Background: Primary central nervous system lymphoma (PCNSL) is rare and there is limited genomic and immunological information available. Incidental clinical and radiographic responses have been reported in PCNSL patients treated...